Role of endothelin-1 in the skin fibrosis of systemic sclerosis

被引:25
作者
Jing, J. [1 ]
Dou, T. T. [1 ]
Yang, J. Q. [1 ]
Chen, X. B. [1 ]
Cao, H. L. [1 ]
Min, M. [1 ]
Cai, S. Q. [1 ]
Zheng, M. [1 ]
Man, X. Y. [1 ]
机构
[1] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Dermatol, Hangzhou 310009, Zhejiang, Peoples R China
关键词
endothelin-1; systemic sclerosis; fibroblast; smad; Akt; RAYNAUDS-PHENOMENON; OPEN-LABEL; TGF-BETA; SCLERODERMA; FIBROBLASTS; ACTIVATION; EXPRESSION; BOSENTAN;
D O I
10.1684/ecn.2015.0360
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Endothelin-1 (ET-1) acts as a key regulator of vasoconstriction and fibrosis. Many previous studies have focused on the role of ET-1 in scleroderma (systemic sclerosis, SSc). We investigated the effects of ET-1 on the production of extracellular matrix in SSc and normal skin fibroblasts. Primary cultured dermal fibroblasts from SSc patients and healthy controls were treated with ET-1 (25 ng/mL) for 0 min, 15 min, 1 h, 24 h, 48 h and 72 h, respectively. Our results showed that, in SSc fibroblasts, ET-1 upregulated collagen type I, connective tissue growth factor (CTGF), type I plasminogen activator inhibitor (PAI-1) and pAkt in a time-dependent manner within 72 h; in normal fibroblasts, 25 ng/mL ET-1 stimulation correlated with high levels of CTGF, PAI-1 and pAkt. The secretion of fibronectin (FN), collagen type I, and PAI-1 is markedly increased in the supernatant of both SSc fibroblasts and normal fibroblasts. Furthermore, ET-1 phosphorylates Smad2 and Smad3 in normal fibroblasts, but not in SSc fibroblasts. In conclusion, our results demonstrated that ET-1 may induce fibrosis in dermal fibroblasts through Akt signals.
引用
收藏
页码:10 / 14
页数:5
相关论文
共 27 条
  • [1] Aghaei Mehrdad, 2012, Indian Dermatol Online J, V3, P14, DOI 10.4103/2229-5178.93484
  • [2] PRELIMINARY CRITERIA FOR THE CLASSIFICATION OF SYSTEMIC-SCLEROSIS (SCLERODERMA)
    不详
    [J]. ARTHRITIS AND RHEUMATISM, 1980, 23 (05): : 581 - 590
  • [3] Davenport A. P., 2006, V176, P295
  • [4] Effect of Bosentan on Systemic Sclerosis-associated Interstitial Lung Disease Ineligible for Cyclophosphamide Therapy: A Prospective Open-label Study
    Furuya, Yoshiaki
    Kuwana, Masataka
    [J]. JOURNAL OF RHEUMATOLOGY, 2011, 38 (10) : 2186 - 2192
  • [5] PAI-1 in tissue fibrosis
    Ghosh, Asish K.
    Vaughan, Douglas E.
    [J]. JOURNAL OF CELLULAR PHYSIOLOGY, 2012, 227 (02) : 493 - 507
  • [6] BOSENTAN TREATMENT FOR RAYNAUD'S PHENOMENON AND SKIN FIBROSIS IN PATIENTS WITH SYSTEMIC SCLEROSIS AND PULMONARY ARTERIAL HYPERTENSION: AN OPEN-LABEL, OBSERVATIONAL, RETROSPECTIVE STUDY
    Giordano, N.
    Puccetti, L.
    Papakostas, P.
    Di Pietra, N.
    Bruni, F.
    Pasqui, A. L.
    Acampa, M.
    Bocchi, V.
    Donati, V.
    Voglino, M.
    Fioravanti, A.
    Montella, A.
    Auteri, A.
    Nuti, R.
    Pastorelli, M.
    [J]. INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 2010, 23 (04) : 1185 - 1193
  • [7] The endothelins in the pulmonary system
    Goldie, RG
    Knott, PG
    Carr, MJ
    Hay, DWP
    Henry, PJ
    [J]. PULMONARY PHARMACOLOGY & THERAPEUTICS, 1996, 9 (02) : 69 - 93
  • [8] Expression of decorin throughout the murine hair follicle cycle: hair cycle dependence and anagen phase prolongation
    Jing, Jing
    Wu, Xian-jie
    Li, Yun-ling
    Cai, Sui-Qing
    Zheng, Min
    Lu, Zhong-Fa
    [J]. EXPERIMENTAL DERMATOLOGY, 2014, 23 (07) : 486 - 491
  • [9] Scleroderma fibroblasts demonstrate enhanced activation of Akt (protein kinase B) in situ
    Jun, JB
    Kuechle, M
    Min, J
    Shim, SC
    Kim, G
    Montenegro, V
    Korn, JH
    Elkon, KB
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2005, 124 (02) : 298 - 303
  • [10] ENDOTHELIN, AN ENDOTHELIAL-DEPENDENT VASOCONSTRICTOR IN SCLERODERMA - ENHANCED PRODUCTION AND PROFIBROTIC ACTION
    KAHALEH, MB
    [J]. ARTHRITIS AND RHEUMATISM, 1991, 34 (08): : 978 - 983